Aktiesnakken — Januar 2010
-
-
hvem anmelder til finanstilsynet?
-
CHMP, er det noget lign. det advisory board der stemte 11-3 for arzerra i maj 09?
-
og hvem anmelder RBB for misinformation?
-
Genmab får betinget Arzerra-godkendelse i Europa
-
det er vel måske nok lige at stramme den
-
Biotekselskabet Genmab har sammen med partneren GlaxoSmithKline fået en
betinget godkendelse af midlet Arzerra til behandling af refraktær -
refraktær kronisk
lymfatisk leukæmi, CLL, i Europa. Det oplyser selskabet i en meddelelse. -
erklæring fra CHMP = betinget godkendelse?.....
-
så kører vi - eller skal vi 40% ned på en godkendelse igen?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind